A novel combined carbohydrate antigen 19-9 and lymphocyte-to-monocyte ratio score can predict early recurrence of resectable pancreatic ductal adenocarcinoma

[1]  C. Kang,et al.  Systemic inflammation response index correlates with survival and predicts oncological outcome of resected pancreatic cancer following neoadjuvant chemotherapy. , 2022, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[2]  T. Notake,et al.  Preoperative Peripheral Blood Lymphocyte-to-Monocyte Ratio Predicts Long-Term Outcome for Patients with Pancreatic Ductal Adenocarcinoma , 2021, Annals of Surgical Oncology.

[3]  K. Ishido,et al.  Development of a Biomarker-Based Scoring System Predicting Early Recurrence of Resectable Pancreatic Duct Adenocarcinoma , 2021, Annals of Surgical Oncology.

[4]  T. Utsunomiya,et al.  Prognostic significance of preoperative PNI and CA19-9 for pancreatic ductal adenocarcinoma: A multi-institutional retrospective study. , 2021, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[5]  Y. Oda,et al.  Lymphocyte–C-reactive protein ratio as a prognostic marker associated with the tumor immune microenvironment in intrahepatic cholangiocarcinoma , 2021, International Journal of Clinical Oncology.

[6]  L. Matrisian,et al.  Estimated Projection of US Cancer Incidence and Death to 2040 , 2021, JAMA network open.

[7]  M. Schell,et al.  Neutrophil to lymphocyte ratio, not platelet to lymphocyte or lymphocyte to monocyte ratio, is predictive of patient survival after resection of early-stage pancreatic ductal adenocarcinoma , 2020, BMC Cancer.

[8]  Ling Lin,et al.  A preoperative risk model for early recurrence after radical resection may facilitate initial treatment decisions concerning the use of neoadjuvant therapy for patients with pancreatic ductal adenocarcinoma. , 2020, Surgery.

[9]  S. Hayami,et al.  Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer. , 2019, Surgery.

[10]  N. Yamanaka,et al.  A combination of platelet-to-lymphocyte ratio and carbohydrate antigen 19-9 predict early recurrence after resection of pancreatic ductal adenocarcinoma. , 2019, Annals of translational medicine.

[11]  G. Honda,et al.  Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05). , 2019, Japanese journal of clinical oncology.

[12]  I. Endo,et al.  Role of the tumor microenvironment in pancreatic cancer , 2019, Annals of gastroenterological surgery.

[13]  Jae Hoon Lee,et al.  Chronologic changes in clinical and survival features of pancreatic ductal adenocarcinoma since 2000: A single‐center experience with 2,029 patients , 2018, Surgery.

[14]  E. Nakakura,et al.  Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

[15]  San-yuan Hu,et al.  Neoadjuvant therapy in pancreatic cancer: a systematic review and meta‐analysis of prospective studies , 2017, Cancer medicine.

[16]  D. Gouma,et al.  The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After , 2017, Surgery.

[17]  K. Hirakawa,et al.  Preoperative predictors for early recurrence of resectable pancreatic cancer , 2017, World Journal of Surgical Oncology.

[18]  Zuqiang Liu,et al.  Prognostic Value of the CRP/Alb Ratio, a Novel Inflammation-Based Score in Pancreatic Cancer , 2017, Annals of Surgical Oncology.

[19]  M. Rutkowska,et al.  Preoperative Neutrophil-Lymphocyte and Lymphocyte-Monocyte Ratios Reflect Immune Cell Population Rearrangement in Resectable Pancreatic Cancer , 2016, Annals of Surgical Oncology.

[20]  T. Misawa,et al.  The C-reactive Protein to Albumin Ratio Predicts Long-Term Outcomes in Patients with Pancreatic Cancer After Pancreatic Resection , 2016, World Journal of Surgery.

[21]  M. Ikeguchi,et al.  Prognostic indicators based on inflammatory and nutritional factors after pancreaticoduodenectomy for pancreatic cancer , 2016, Surgery Today.

[22]  G. Honda,et al.  Proposed preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after surgical resection: A multi-center retrospective study. , 2015, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[23]  C. Sakakura,et al.  Optimal duration of the early and late recurrence of pancreatic cancer after pancreatectomy based on the difference in the prognosis. , 2014, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[24]  H. Furukawa,et al.  Serum CA19-9 is a Significant Predictor among Preoperative Parameters for Early Recurrence after Resection of Pancreatic Adenocarcinoma , 2012, Journal of Gastrointestinal Surgery.

[25]  Tae Hyun Kim,et al.  CA 19-9 level as indicator of early distant metastasis and therapeutic selection in resected pancreatic cancer. , 2011, International journal of radiation oncology, biology, physics.

[26]  Marcus D. Ruopp,et al.  Youden Index and Optimal Cut‐Point Estimated from Observations Affected by a Lower Limit of Detection , 2008, Biometrical journal. Biometrische Zeitschrift.